Work

Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma

Year: 2017

Type: article

Abstract: Summary: Assessing the benefit of routine panel-based genomic sequencing of tumor tissue remains a critical need in clinical oncology. Jordan and coauthors report on 860 patients with metastatic or recurrent lung adenocarcinoma from a single institution with prospectively sequenced tumors using a targeted gene panel of >300 genes to guide therapy. Their results suggest that early prospective tumor sequencing, including non–standard-of-care predictive biomarkers combined with careful clinical annotation, can guide therapy, improve clinical outcomes, and accelerate the development of biomarkers and drugs. Cancer Discov; 7(6); 555–7. ©2017 AACR. See related article by Jordan et al., p. 596.

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-17-0355

Authors: David Liu, Natalie I. Vokes, Eliezer M. Van Allen

Institution: Dana-Farber Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute